Search

Displaying results 1181 - 1190 of 10000 in total
  1. Drug

    Gluconic Acid

    go.drugbank.com/drugs/DB13180
    ApprovedInvestigational

    Gluconic acid or gluconate is used to maintain the cation-anion balance on electrolyte solutions.

    Mixtures: Isolyte S, Isolyte S pH 7.4Synonyms: D-Gluconic Acid
  2. Drug

    Sodium phosphate, dibasic

    go.drugbank.com/drugs/DB14502
    ApprovedInvestigational

    Synonyms: Phosphoric acid, sodium salt (1:2)Mixtures: ISOLYTE-S PH 7.4 PVC 500 ML(SETLI), ISOLYTE-S PH 7.4 PVC 1000 ML(SETLI)
  3. Drug

    Ivosidenib

    go.drugbank.com/drugs/DB14568
    ApprovedInvestigational

    Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. … The drug is only effective in patients with a susceptible IDH1 mutation.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  4. Target

    Neuronal acetylcholine receptor subunit alpha-10

    go.drugbank.com/bio_entities/BE0000411
    TargetHumans

    by a collection of nAChR subunits. … Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability. nAChRs are excitatory neurotrasnmitter receptors formed

    Synonyms: NACHR alpha-10
  5. Drug

    Tirzepatide

    go.drugbank.com/drugs/DB15171
    ApprovedInvestigational

    Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor … Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

    Categories: GLP-1 Agonists, Receptors, G-Protein-CoupledProducts: Mounjaro 5 mg/0,5 ml Enjeksiyonluk Çözelti, 1 ADET, Mounjaro 5 mg/0,5 ml Enjeksiyonluk Çözelti, 4 ADET
  6. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    [A236544] So far, finerenone is the only nonsteroidal mineralocorticoid receptor antagonist to be FDA approved. … [A236544] Eplerenone is more selective and has longer lasting effects.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  7. Drug

    Migalastat

    go.drugbank.com/drugs/DB05018
    ApprovedInvestigational

    [L47036,L47057] As of August 2018, migalastat under Amicus Therapeutics' brand name Galafold is currently approved in Australia, Canada, European Union, Israel, Japan, South Korea, Switzerland, and … Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A).

    Categories: Alpha-Galactosidase A (alpha-Gal A) Pharmacological Chaperones, Heterocyclic Compounds, 1-RingSynonyms: (2R,3S,4R,5S)-2-(Hydroxymethyl)piperidine-3,4,5-triol, 1-Deoxygalactostatin
  8. Drug

    Influenza A virus A/Guangdong-Maonan/SWL1536/2019 CNIC-1909 (H1N1) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB15703
    ApprovedInvestigational

    A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3.

    Mixtures: INFLUVAC S TETRA, INFLUVAC S TETRASynonyms: Influenza A virus A/Guangdong-Maonan/SWL1536/2019 CNIC-1909 (H1N1) antigen (formaldehyde inactivated)
  9. Drug

    RUS 3108

    go.drugbank.com/drugs/DB05911
    Experimental

    The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers. … RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories.

  10. Drug

    Masitinib

    go.drugbank.com/drugs/DB11526
    InvestigationalVet approved

    Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in dogs. It has been available in Europe since 2009, under the brand name Masivet. … In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.

    Categories: Heterocyclic Compounds, 1-RingSynonyms: 4-((4-METHYLPIPERAZIN-1-YL)METHYL)-N-(4-METHYL-3-((4-PYRIDIN-3-YL-1,3-THIAZOL-2-YL)AMINO)PHENYL)BENZAMIDE